news subscription

ENROFLON® GEL - A CLEAR CHOICE FOR EFFECTIVE TREATMENT OF MASTITIS IN COWS

VIC Group of Companies has launched a new fixed-dose anti-infective drug for the treatment of subclinical and clinical bacterial mastitis in cows - ENROFLON® GEL. 

ENROFLON® GEL is a broad-spectrum drug with antibacterial effect against most gram-positive and gram-negative microorganisms, including Staphylococcus spp., Streptococcus agalactiae, Streptococcus uberis, Streptococcus dysagalactiae, Corynebacterium pyogenes, Escherichia coli, Pseudomonas aeruginosa, Bacillus spp., Pasteurella spp. and others, and has anti-inflammatory, analgesic and antipyretic effects. Its two active constituents are: enrofloxacin, having high potency against the main mastitis agents, and ketoprofen (NSAID).

 ENROFLON® GEL is administered intercisternally into the infected quarters, evenly distributed in the udder tissues and shows rapid achievement of curative concentrations of active substances.  The drug is administered to animals twice a day with an interval of 12 hours for 2-3 days.

 ENROFLON® GEL is approved for animal use during pregnancy and lactation.

The drug has a short milk withholding period - 72 hours.

The ENROFLON® GEL intercisternal treatment has no direct analogues in the veterinary preparations market.  

ENROFLON® GEL is a well-founded choice for mastitis treatment in cows.

 

All news

Наверх